Guided Therapeutics : Nigerian Clinical Studies Demonstrate Advantages of LuViva® Advanced Cervical Scan for Screening and Detecting Cervical Pre-Cancer in Africa
Envoyer par mail
11/26/2014 | 07:14pm US/Eastern
By a News Reporter-Staff News Editor at Cancer Weekly -- Results of two clinical studies of the LuViva® Advanced Cervical Scan showed the versatility of the technology in its ability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods. The studies were presented at the Society of Gynecology and Obstetrics of Nigeria 2014 conference in Asaba, Nigeria, this week (see also Guided Therapeutics, Inc.).
The LuViva, developed by Guided Therapeutics, Inc. (OTCBB:GTHP) (OTCQB:GTHP), is designed to eliminate costly, painful and unnecessary follow up testing following a positive Pap, human papillomavirus (HPV) or other screening test.
In a 100-patient study led by Professor Issac Adewole, MD, Principal Investigator for cervical cancer for Nigeria, and conducted at University Teaching Hospital, Ibadan, Nigeria, it was concluded that LuViva was able to detect 100% of serious pre-cancer (Cervical intraepithelial neoplasia 2+, CIN2+) while eliminating up to 40% of false positive results, or women who were actually disease free, from further testing. These results are consistent with other published studies conducted in North America. Three of the CIN2+ cases correctly identified by LuViva tested negative for HPV at the time of the study.
"These results are encouraging and demonstrate the value of LuViva as a means to detect cervical disease, even in the absence of a positive human papillomavirus result, while also providing a means to reduce unnecessary additional testing," said Professor Adewole. "In addition to the accuracy displayed in the study, LuViva is painless and results are immediate, important attributes for the patient and healthcare provider, particularly in rural communities."
The second study looked at LuViva as a tool for primary screening where Pap tests are not available. The study enrolled 254 women and was led by Professor B. Olusola Fasubaa, Commissioner of the State Ministry of Health, Ekiti State, Nigeria. In the study, LuViva classified 13% of the women as having a greater than normal likelihood of cervical disease. These results are similar to those presented in 2012 at the American Society of Colposcopy and Cervical Pathology and with other to be published screening studies and support the potential of LuViva as a primary screening modality.
Keywords for this news article include: Cancer, Oncology, Guided Therapeutics Inc..
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx
